COgnitioN With VERiciGuat Evaluation in Heart Failure

Recruiting now · Phase 2

Conditions studied: Heart Failure, Cognitive Impairment

In brief

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Key facts

Study ID: NCT06601465
Run by: University of Alberta
People needed: 120
Starts: 2025-06-03
Expected to finish: 2027-05-01
Last updated by the study team: 2025-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult patients
Established chronic heart failure (≥ 6 months)
Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).

You may not qualify if…

Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding)
Unable to undergo CMR imaging or brain MRI.
CMR exclusions: incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias).
General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures [coronary angioplasty and/or surgical revascularization in the previous 3 months], cancer/malignancy, or with severe dementia).
Patients with allergies to the study products.
Patients currently hospitalized.

Where it is running

University of Calgary — Calgary, Alberta, Canada (enrolling)
University of Alberta — Edmonton, Alberta, Canada (enrolling)
University of Ottawa — Ottawa, Ontario, Canada (enrolling)
McGill University Health Center — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.